Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares and 0% beneficial ownership of Common Stock as of the amendment. The filing notes an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.
GE HealthCare Technologies Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 7, 2026. Holders of 456,290,143 common shares as of March 9, 2026 can vote on three items: electing eight directors for one-year terms, an advisory say‑on‑pay vote on 2025 executive compensation, and ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights 2025 revenue of $20.6 billion, record backlog, and earnings per share growth driven by volume and productivity despite tariff impacts. The board emphasizes strong governance, with seven of eight nominees independent, majority voting, proxy access, no poison pill or dual‑class shares, and a 15‑year director term limit. Executive pay is positioned as performance‑based and long‑term, with rigorous stock ownership requirements, a broad clawback policy, and prohibitions on hedging and pledging.
Lobo Kevin reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. director Kevin Lobo received an equity award of 777 restricted stock units of common stock. These RSUs were granted at no cash cost to him and represent compensation rather than an open-market purchase or sale.
According to the award terms, 100% of the 777 restricted stock units will vest on the earlier of GE HealthCare’s next annual meeting of stockholders or March 13, 2027. Each vested unit entitles him to receive one share of GE HealthCare common stock, and settlement may be deferred under the company’s non-employee director compensation plan.
GE HealthCare Technologies Inc. director Kevin Lobo filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing establishes his reporting status as a director but does not report any insider stock transactions or positions in this excerpt.
GE HealthCare Technologies Inc. reported that its Board appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. His term runs until the 2026 Annual Meeting and he will be compensated under the company’s standard non-employee director program, with an indemnification agreement matching the form used for other directors.
The company also disclosed that directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting due to other commitments, and their decisions do not reflect any disagreement with the company. A press release announcing Mr. Lobo’s appointment was issued on March 17, 2026 and furnished as an exhibit.
Bankes Jeannette reported acquisition or exercise transactions in this Form 4 filing.
GE HealthCare Technologies Inc. reported that Jeannette Bankes, CEO of Patient Care Solutions, received new equity awards. On March 2, 2026, she was granted an employee stock option for 18,038 shares of common stock and 6,861 restricted stock units, both at no cash cost.
The restricted stock units each represent one share of GE HealthCare common stock and are scheduled to vest 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029. The stock option becomes exercisable on the same 33/33/34 schedule. Following these awards, she directly holds 43,892 shares of common stock and 18,038 options.